Camrelizumab + Pemetrexed + Carboplatin
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-squamous Non-small-cell Lung Cancer
Conditions
Non-squamous Non-small-cell Lung Cancer, Brain Metastases
Trial Timeline
Jan 15, 2020 → Dec 30, 2022
NCT ID
NCT04211090About Camrelizumab + Pemetrexed + Carboplatin
Camrelizumab + Pemetrexed + Carboplatin is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Non-squamous Non-small-cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04211090. Target conditions include Non-squamous Non-small-cell Lung Cancer, Brain Metastases.
What happened to similar drugs?
3 of 20 similar drugs in Non-squamous Non-small-cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04211090 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Non-squamous Non-small-cell Lung Cancer